NOV-002, a mimetic of glutathione disulfide

Expert Opinion on Investigational Drugs

Volumn 17, Issue 7, 2008, Pages 1075-1083

  Townsend, Danyelle M ^a   Pazoles, Christopher J ^b   Tew, Kenneth D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Novelos Therapeutics Inc   (United States)

Author keywords

Biomarkers; Glutathione; Lung cancer; Redox; S glutathionylation; Thiols

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CITUXIMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ETOPOSIDE; GAMMA GLUTAMYLTRANSFERASE; GEFITINIB; GLUTATHIONE DISULFIDE; JANUS KINASE 2; LOMUSTINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; NOV 002; PACLITAXEL; PROTEIN DISULFIDE ISOMERASE; RESVERATROL; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TLK 199; VASCULAR TARGETING AGENT;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER PAIN; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG MIXTURE; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OXIDATION REDUCTION STATE; SINGLE DRUG DOSE;

ANIMALS; CISPLATIN; DRUG COMBINATIONS; DRUG TOLERANCE; GLUTATHIONE DISULFIDE; HUMANS; MOLECULAR MIMICRY; MOLECULAR STRUCTURE;

EID: 48249115538     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.7.1075     Document Type: Article

References (31)

1. Pazoles CJ, Gernstein H. NOV-002, a chemoprotectant/immunomodulator, added to first line carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): a randomized phase 1/2, open label, controlled study. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 2006;24(18S Supplement):17021
2. Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 1988;48(13):3622-5
3. Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997;89(23):1789-96
4. O'dwyer PJ, Lacreta F, Nash S, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991;51(22):6059-65
5. Ruscoe JE, Rosario LA, Wang T, et al. Pharmacologic of genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001;298(1):339-45
6. Gate L, Majumdar RS, Lunk A, et al. Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways. J Biol Chem 2004;279(10):8608-16
7. Adler V, Yin Z, Fuchs SY, et al. Regulation of JNK signaling by GSTp. EMBO J 1999;18(5):1321-34
8. Wang T, Arifoglu P, Ronai Z, et al. Glutathione S -transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001;276(24):20999-1003
9. Peterson J D, Herzenberg LA, Vasquez K, et al. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci USA 1998;95(6):3071-6
10. Herzenberg LA, De Rosa SC, Dubs JG, et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997;94(5):1967-72
11. El Maalouf G, Rodier JM, Faivre S, et al. Could we expect to improve survival in small cell lung cancer? Lung Cancer 2007;57(Suppl 2):S30-4
12. Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 2007;25(26):4137-45
13. Rigas JR, Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007;2(Suppl 2):S77-85
14. Townsend DM, HE L, Hutchens S, et al. NOV-002, a glutathione disulfide, mimetic, as a modulator of cellular redox balance. Cancer Res 2008;68:2870-7
15. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988;263(33):17205-8
16. Wang J, Boja ES, Tan W, et al. Reversible glutathionylation regulates actin polymerization in A431 cells. J Biol Chem 2001;276(51):47763-6
17. Townsend DM. S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol Interv 2007;7(6):313-24
18. Brennan JP, Miller JI, Fuller W, et al. The utility of N,N-biotinyl glutathione disulfide in the study of protein S-glutathiolation. Mol Cell Proteomics 2006;5(2):215-25
19. Pompella A, Corti A, Paolicchi A, et al. Gamma-glutamyltransferase, redox regulation and cancer drug resistance. Curr Opin Pharmacol 2007;7(4):360-6
20. Sekhar KR, Spitz DR, Harris S, et al. Redox-sensitive interaction between KIAA0132 and Nrf2 mediates indomethacin-induced expression of gamma-glutamylcysteine synthetase. Free Radic Biol Med 2002;32(7):650-62
21. 2 production and S-thiolation. Free Radic Biol Med 1999;27:623-35
22. Jordan PA, Gibbins JM. Extracellular disulfide exchange and the regulation of cellular function. Antioxid Redox Signal 2006;8(3-4):312-24
23. Matthias LJ, Hogg PJ. Redox control on the cell surface: implications for HIV-1 entry. Antioxid Redox Signal 2003;5(1):133-8
24. Lihav J, Wijnen EM, Hess O, et al. Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. Blood 2003;102(6):2085-92
25. Goplen D, Wang J, Enger PO, et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006;66(20):9895-902
26. Smith J, Ladi E, Mayer-Proschel M, et al. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci USA 2000;97(18):10032-7
27. Noble M, Mayer-Proschel M, Proschel C. Redox regulation of precursor cell function: insights and paradoxes. Antioxid Redox Signal 2005;7(11-12):1456-67
28. O'shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109(Suppl):S121-31
29. Tew KD. Redox in redux. emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol 2007;73(9):1257-69
30. Filomeni G, Aquilano K, Civitareale P. et al. Activation of c-Jun-N-terminal kinase is required for apoptosis triggered by glutathione disulfide in neuroblastoma cells. Free Radic Biol Med 2005;39(3):345-54
31. Filomeni G, Rotilio G, Ciriolo MR. Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 MAP kinase pathway. FASEB J 2003;171:64-6